Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 25,519 Shares of Company Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $80.23, for a total transaction of $2,047,389.37. Following the transaction, the director directly owned 12,991 shares of the company’s stock, valued at approximately $1,042,267.93. This trade represents a 66.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

• On Tuesday, October 20th, Kevin Bitterman sold 5,312 shares of Disc Medicine stock. The stock was sold at an average price of $79.95, for a total transaction of $424,694.40.
• On Monday, October 19th, Kevin Bitterman sold 10,994 shares of Disc Medicine stock. The stock was sold at an average price of $79.97, for a total transaction of $879,190.18.
• On Friday, September 11th, Kevin Bitterman sold 27,136 shares of Disc Medicine stock. The stock was sold at an average price of $70.11, for a total transaction of $1,902,504.96.
• On Friday, September 4th, Kevin Bitterman sold 1,689 shares of Disc Medicine stock. The shares were sold at an average price of $79.96, for a total transaction of $135,052.44.
• On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The shares were sold at an average price of $79.98, for a total transaction of $416,135.94.
• On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The shares were sold at an average price of $80.17, for a total transaction of $3,941,477.88.
• On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The stock was sold at an average price of $79.95, for a total value of $10,313.55.

Disc Medicine Stock Performance

Shares of IRON opened at $76.00 on Thursday. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average price is $71.44 and its 200-day moving average price is $71.47. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The stock has a market cap of $2.92 billion, a P/E ratio of -11.55 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. Equities research analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. BMO Capital Markets increased their target price on Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Disc Medicine in a report on Thursday, September 10th. Wedbush lifted their price target on Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday. Truist Financial upped their price target on shares of Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Cantor Fitzgerald increased their price objective on shares of Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a research report on Monday. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System lifted its position in Disc Medicine by 2.4% in the 2nd quarter. Arizona State Retirement System now owns 6,844 shares of the company’s stock valued at $501,000 after acquiring an additional 160 shares in the last quarter. AlphaCentric Advisors LLC boosted its stake in Disc Medicine by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after purchasing an additional 216 shares during the last quarter. State of Wyoming purchased a new stake in Disc Medicine during the 2nd quarter valued at $25,000. Entropy Technologies LP boosted its stake in Disc Medicine by 9.9% during the 1st quarter. Entropy Technologies LP now owns 4,788 shares of the company’s stock valued at $306,000 after purchasing an additional 431 shares during the last quarter. Finally, Allworth Financial LP bought a new stake in shares of Disc Medicine in the 2nd quarter worth $46,000. Institutional investors own 83.70% of the company’s stock.

Key Headlines Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Analyst price targets increased: Jefferies raised its price target to $149, while Cantor Fitzgerald lifted its target to $170 following positive Phase 3 results for bitopertin. The upgrades reinforce optimism about the drug’s potential in erythropoietic protoporphyria and related conditions. Jefferies raises Disc Medicine price target Cantor Fitzgerald raises Disc Medicine price target
• Positive Sentiment: $450 million financing strengthens the balance sheet: Disc Medicine priced an upsized offering of 6 million shares at $75 per share, with a possible 900,000-share overallotment. Proceeds will fund clinical development, research, and potential commercialization of bitopertin, potentially reducing financing risk and extending the company’s operating runway. Disc Medicine announces $450 million offering
• Neutral Sentiment: Unusually high options activity indicates elevated trading interest and expectations for volatility, but the report does not establish a clear directional signal. Disc Medicine sees unusually high options volume
• Negative Sentiment: Share dilution is weighing on the stock: The sale of 6 million new shares—following the previously announced $350 million offering—can reduce existing shareholders’ ownership percentage and create selling pressure around the $75 offering price.
• Negative Sentiment: Director selling adds an overhang: Director Kevin Bitterman sold a combined 41,825 shares for approximately $3.35 million across October 19–21, materially reducing his direct holdings. The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which makes them less informative about current management expectations but still represents potential supply. Disc Medicine insider transaction filing

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.